


RECEIVED
CENTRAL FAX CENTER
JAN 17 2007

CURRENT LISTING OF CLAIMS

1. (currently amended) A compound according to formula I




wherein

R^1 is selected from the group consisting of C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} alkenyl, C_{3-6} alkynyl, C_{3-7} cycloalkyl, C_{1-3} alkoxy- C_{1-3} alkyl, phenyl and benzyl, wherein, said phenyl and said benzyl optionally substituted with one to three substituents independently selected from the group consisting of C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy,

C_{1-6} haloalkoxy, C_{1-6} alkylthio, nitro, halogen and cyano;

R^2 is phenyl or pyridyl optionally substituted with one to three groups independently selected from the group consisting of halogen, cyano, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkoxycarbonyl, and $CONR^6R^7$;

R^3 is substituted C_{1-6} alkyl, substituted C_{1-3} alkoxy- C_{1-3} alkyl, substituted C_{3-6} alkenyl, C_{3-7} cycloalkyl, optionally substituted C_{1-6} alkoxy, $(CH_2)_nR^5$, $CH(OH)R^5$, $-(CH_2)_n-O-(CH_2)_pR^5$, NR^6R^7 , $C(=Y)Z[[,]]$ or $-X(C=Y)Z$ or $-Ha-e$;




wherein,

said alkyl, said C_{1-3} alkoxy- C_{1-3} alkyl and said alkenyl are substituted by $-OH$, $-NR^6R^7$, $-C(=Y)Z$, $-X(C=Y)Z$, CN , $-S(O)_q-C_{1-6}$ alkyl; $-SO_2NR^6R^7$, $-SO_2NHNH_2$, or $-NR^6SO_2-C_{1-6}$ alkyl;

said alkoxy is optionally substituted by $-OH$, $-NR^6R^7$, $-C(=Y)Z$, $-X(C=Y)Z$, $-S(O)_q-C_{1-6}$ alkyl; $-SO_2NR^6R^7$ or $-SO_2NHNH_2$;

R^{12} is hydrogen, C_{1-6} alkyl or $-C(=Y)Z$;

R^3 is a phenyl or a heteroaryl ring according to formula ~~IIIa-IIIh~~ said phenyl and said heteroaryl ring optionally substituted with halo, $-OR^6$, $-NR^6R^7$, $-C(=O)Z$, $-X(C=O)Z$;



wherein

X^1 is selected from the group consisting of $-R^{10}C=CR^{10a}$, $-O-$, $-S-$, $-NR^6$ and $-CHR^6$;

X^2 is selected from the group consisting of $-R^{10}C=CR^{10a}$, $-O-$, $-S-$, and $-CHR^6$;

X^3 is selected from the group consisting of hydrogen, hydroxyl and thiol;

R^{10} and R^{10a} are independently selected from the group consisting of hydrogen or C_{1-6} alkyl optionally substituted with one or two substituents independently selected from the group consisting of hydroxy, C_{1-6} alkoxy, thiol, C_{1-6} alkylthio, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyl, halogen, amino, C_{1-6} alkylamino, C_{1-3} dialkylamino, amino C_{1-3} alkyl, C_{1-3} alkylamino C_{1-3} alkyl, and C_{1-3} dialkylamino C_{1-3} alkyl;

said phenyl and said heteroaryl ring is optionally substituted with halo, $-OR^6$, $-NR^6R^7$,

$-C(=O)Z$, $-X(C=O)Z$

R^4 is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl[[,]] C_{3-7} cycloalkyl, C_{1-3} alkoxy C_{1-3} alkyl, $(CH_2)_6R^{11}$ or $(CH_2)_6O(CH_2)_6R^{11}$;

wherein,

said alkyl, said alkenyl[[,]] and said alkynyl and said cycloalkyl are optionally substituted by $-OH$, $-OR^6$, $-NR^6R^7$, $-C(=Y)Z$, $-X(C=Y)Z$, $-S(O)_qC_{1-6}$ alkyl, $-SO_2NR^6R^7$ or $-SO_2NHNH_2$;

R^{11} is a phenyl or a heteroaryl ring selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyrrole, imidazole, pyrazole and thiophene, said heteroaryl ring and said phenyl optionally substituted with one to three groups independently selected from the group consisting of halogen, cyano, C_{1-3} alkyl, C_{1-3} haloalkyl and C_{1-3} alkoxy; or R^{11} is $N[(CH_2)_2]_2W$ wherein W is selected from the group consisting of NR^6 , $(CH_2)_2$, $N(C=O)Z$, $CHOR^6$, CHR^6 , $CHNHC(=O)Z$ and $CHNR^6R^7$;

n , o , p and q are as defined below and s is 0 or 1;

R^6 , R^7 , R^8 and R^9 (i) taken independently are selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-3} alkoxy- C_{1-3} alkyl, C_{1-3} alkylamino- C_{1-3} alkyl and C_{1-3} dialkylamino- C_{1-3} alkyl or (ii) when both R^6 and R^7 are attached to the same nitrogen atom they may be taken together, along with the nitrogen, to form a pyrrolidine, piperidine, piperazine or morpholine;

X , and Y are independently O or NR^6 ;

Z is hydrogen, hydroxyl, C_{1-6} alkoxy, NR^6R^{13} , C_{1-6} alkyl, C_{1-3} alkoxy- C_{1-3} alkyl wherein R^{13} is R^7 or phenyl optionally substituted with one to three groups independently selected from the group consisting of halogen, cyano, C_{1-3} alkyl, C_{1-3} haloalkyl and C_{1-3} alkoxy;

n is 0 to 3;

o and p are independently 0 to 4 and $o + p \leq 5$;

q is 0 to 2; and,

k , $r1$ and $r2$ are independently 0 to 4, and $5 \geq (r1 + r2) \geq 2$; and,

acid addition salts, hydrates and solvates thereof, with the proviso that when R^4 is $(CH_2)_nR^{11}$, n is 1 and R^{11} is substituted phenyl, R^2 is other than unsubstituted phenyl.

2. (currently amended) A compound according to claim 1 wherein:

R^1 is selected from the group consisting of C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-7} cycloalkyl, C_{1-3} alkoxy- C_{1-3} alkyl and optionally-substituted phenyl; and

R^2 is optionally substituted phenyl; and,

R^4 is C_{1-6} alkyl[[l]] C_{3-7} cycloalkyl, $(CH_2)_nR^{11}$ or $(CH_2)_nO(CH_2)_pR^{11}$; wherein, said alkyl and said cycloalkyl are optionally substituted by $-OH$, $-OR^6$, $-NR^8R^9$, $-C(=Y)Z$ or $-X(C=Y)Z[[l]]$.

R^{11} is a phenyl optionally substituted with one to three groups independently selected from the group consisting of halogen, cyano, C_{1-3} alkyl, C_{1-3} haloalkyl and C_{1-3} alkoxy.


3. (currently amended) A compound according to claim 2 wherein R^3 is substituted C_{1-6}

alkyl[[,]] ~~IIa-e~~ or $-(CH_2)_nR^5$ wherein R^5 is ~~IIa-IIIh~~.

4. (original) A compound according to claim 2 wherein R^3 is $-(CH_2)_nNR^6R^7$, $-(CH_2)_nC(=O)Z$ or $-(CH_2)_nXC(=O)Z$.

5 - 16. (canceled)

17. (currently amended) A pharmaceutical composition comprising a therapeutically effective quantity of a compound of formula I




wherein

R^1 is selected from the group consisting of C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} alkenyl, C_{3-6} alkynyl, C_{3-7} cycloalkyl, C_{1-3} alkoxy- C_{1-3} alkyl, phenyl and benzyl, wherein, said phenyl and said benzyl optionally substituted with one to three substituents independently selected from the group consisting of C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{1-6} alkylthio, nitro, halogen and cyano;

R^2 is phenyl or pyridyl optionally substituted with one to three groups independently selected from the group consisting of halogen, cyano, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkoxycarbonyl, and $CONR^6R^7$;

R^3 is substituted C_{1-6} alkyl, substituted C_{1-3} alkoxy- C_{1-3} alkyl, substituted C_{3-6} alkenyl, C_{3-7} cycloalkyl, optionally substituted C_{1-6} alkoxy, $-(CH_2)_nR^5$, $-CH(OH)R^5$, $-(CH_2)_6O-(CH_2)_pR^5$, $-NR^6R^7$, $-C(=Y)Z$, or $-X(C=Y)Z$ or ~~IIa-e~~;




wherein,

said alkyl, said C_{1-3} alkoxy- C_{1-3} alkyl and said alkenyl are substituted by -OH, $-NR^6R^7$, $-C(=Y)Z$, $-X(C=Y)Z$, CN, $-S(O)_q-C_{1-6}$ alkyl, $-SO_2NR^6R^7$, $-SO_2NHNH_2$ or $-NR^6SO_2-C_{1-6}$ alkyl;

said alkoxy is optionally substituted by -OH, $-NR^6R^7$, $-C(=Y)Z$, $-X(C=Y)Z$, $-S(O)_q-C_{1-6}$ alkyl, $-SO_2NR^6R^7$ or $-SO_2NHNH_2$;

R^{12} is hydrogen, C_{1-6} alkyl or $-C(=Y)Z$;

R^3 is a phenyl or a heteroaryl ring according to formula ~~IIIa-IIIh~~ optionally substituted with halo, $-OR^6$, $-NR^6R^7$, $-C(=O)Z$, $-X(C=O)Z$;



wherein

X^1 is selected from the group consisting of $R^{10}C=CR^{10a}$, O, S, NR^6 and $-CHR^6$;

X^2 is selected from the group consisting of $R^{10}C=CR^{10a}$, O, S, and $-CHR^6$;

X^3 is selected from the group consisting of hydrogen, hydroxyl and thiol;

R^{10} and R^{10a} are independently selected from the group consisting of hydrogen or C_{1-6} alkyl optionally substituted with one or two substituents independently selected from the group consisting of hydroxy, C_{1-6} alkoxy, thiol, C_{1-6} alkylthio, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyl, halogen, amino, C_{1-6} alkylamino, C_{1-3} dialkylamino, amino- C_{1-3} alkyl, C_{1-3} alkylamino- C_{1-3} alkyl, and C_{1-3} dialkylamino- C_{1-3} alkyl;

said phenyl and said heteroaryl ring optionally substituted with halo, $-OR^6$, $-NR^6R^7$, $-C(=O)Z$, $-X(C=O)Z$;

R^4 is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{2-6} cycloalkyl, C_{1-3} alkoxy- C_{1-3} alkyl, $(CH_2)_n R^{11}$ or $(CH_2)_n O (CH_2)_p R^{11}$; wherein,

said alkyl, said alkenyl, said alkynyl and said cycloalkyl are optionally substituted by $-OH$, $-OR^6$, $-NR^8 R^9$, $-C(=Y)Z$, $-X(C=Y)Z$, $-S(O)_q C_{1-6}$ alkyl, $-SO_2 NR^6 R^7$ or $-SO_2 NHNH_2$;

R^{11} is a phenyl or a heteroaryl ring selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyrrole, imidazole, pyrazole and thiophene, said heteroaryl ring and said phenyl optionally substituted with one to three groups independently selected from the group consisting of halogen, cyano, C_{1-3} alkyl, C_{1-3} haloalkyl and C_{1-3} alkoxy; or R^{11} is $N[(CH_2)_2]_2 W$ wherein W is selected from the group consisting of NR^6 , $(CH_2)_2$, $N(C=O)Z$, $CHOR^6$, $CHR^6 CHNHC(=O)Z$ and $CHNR^6 R^7$;

n , o , p and q are as defined below and s is 0 or 1;

R^6 , R^7 , R^8 and R^9 (i) taken independently are hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-3} alkoxy- C_{1-3} alkyl, C_{1-3} alkylamino- C_{1-3} alkyl or C_{1-3} dialkylamino- C_{1-3} alkyl or (ii) when both R^6 and R^7 are attached to the same nitrogen atom they may be taken together, along with the nitrogen, to form a pyrrolidine, piperidine, piperazine or morpholine;

X , and Y are independently O or NR^6 ;

Z is hydrogen, hydroxyl, C_{1-6} alkoxy, $NR^6 R^{13}$, C_{1-6} alkyl, C_{1-3} alkoxy- C_{1-3} alkyl wherein R^{13} is R^7 or phenyl optionally substituted with one to three groups independently selected from the group consisting of halogen, cyano, C_{1-3} alkyl, C_{1-3} haloalkyl and C_{1-3} alkoxy;

n is 0 to 3;

o and p are independently 0 to 4 and $o + p \leq 5$;

q is 0 to 2;

k , $r1$ and $r2$ are independently 0 to 4, and $5 \geq (r1 + r2) \geq 2$; and,

acid addition salts, hydrates and acid addition salts, hydrates and solvates thereof, with the proviso that when R^4 is $(CH_2)_n R^{11}$, n is 1 and R^{11} is substituted phenyl, R^2 is other than unsubstituted phenyl, in admixture with at least one pharmaceutically acceptable carrier or diluent sufficient upon administration in a single or multiple dose regimen for treating diseases mediated by human immunodeficiency virus or for inhibiting HIV,

* * * * *